BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31613314)

  • 1. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice.
    Butelman ER; Baynard C; McElroy BD; Prisinzano TE; Kreek MJ
    J Psychopharmacol; 2021 May; 35(5):579-590. PubMed ID: 33769112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
    Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
    Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
    Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
    ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
    Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
    Beardsley PM; Howard JL; Shelton KL; Carroll FI
    Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.
    Beardsley PM; Pollard GT; Howard JL; Carroll FI
    Psychopharmacology (Berl); 2010 Jun; 210(2):189-98. PubMed ID: 20372878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term voluntary access to running wheels decreases kappa-opioid antinociception.
    D'Anci KE; Gerstein AV; Kanarek RB
    Pharmacol Biochem Behav; 2000 Jun; 66(2):343-6. PubMed ID: 10880688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
    Solinas M; Goldberg SR
    Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.
    Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS
    Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
    Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
    Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
    Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
    Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
    Bruchas MR; Yang T; Schreiber S; Defino M; Kwan SC; Li S; Chavkin C
    J Biol Chem; 2007 Oct; 282(41):29803-11. PubMed ID: 17702750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress.
    Matsuzawa S; Suzuki T; Misawa M; Nagase H
    Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local administration of mu or kappa opioid agonists attenuates capsaicin-induced thermal hyperalgesia via peripheral opioid receptors in rats.
    Ko MC; Tuchman JE; Johnson MD; Wiesenauer K; Woods JH
    Psychopharmacology (Berl); 2000 Feb; 148(2):180-5. PubMed ID: 10663433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.
    Schank JR; Goldstein AL; Rowe KE; King CE; Marusich JA; Wiley JL; Carroll FI; Thorsell A; Heilig M
    Addict Biol; 2012 May; 17(3):634-47. PubMed ID: 22515275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-type Ca2+ channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats.
    Gullapalli S; Ramarao P
    Neuropharmacology; 2002 Mar; 42(4):467-75. PubMed ID: 11955518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons.
    Su X; Castle NA; Antonio B; Roeloffs R; Thomas JB; Krafte DS; Chapman ML
    Anesth Analg; 2009 Aug; 109(2):632-40. PubMed ID: 19608841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.